key: cord-0902079-todfffw4 authors: Onsongo, S.N.; Otieno, K.; van Duijn, S.; Adams, E.; Omollo, M.; Odero, I.A.; K'Oloo, A.; Houben, N.; Milimo, E.; Aroka, R.; Barsosio, H.C.; Oluoch, F.; Odhiambo, A.; Kariuki, S.; de Wit, T.F. Rinke title: Performance of NowCheck antigen test for SARS-CoV-2 Evaluation of rapid COVID-19 antigen kit date: 2021-11-01 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2021.115591 sha: 3a8f6a14f6a896fe0c31bc4dc1015c49577b511e doc_id: 902079 cord_uid: todfffw4 BACKGROUND: Testing for SARS-CoV-2 in resource-poor settings remains a considerable challenge. Gold standard nucleic acid tests are expensive and depend on expensive equipment and highly trained laboratory staff. More affordable and easier real-time rapid tests are an attractive alternative. This study assessed field performance of such a test in western Kenya. METHODS: We conducted a prospective multi-facility field evaluation study of NowCheck COVID-19 Ag-RDT compared to golden standard PCR. Two pairs of oropharyngeal and nasopharyngeal swabs were collected for comparative analysis. FINDINGS: Of 997 enrolled participants the Ag-RDT had a sensitivity of 84.5% and a specificity of 94.4% with an accuracy of 94.2% at cycle threshold (Ct) value ≤35. Highest sensitivity of 87.7% was observed at Ct ≤ 30 and highest specificity of 97.5% at Ct<40. INTERPRETATION: NowCheck COVID-19 Ag-RDT performed well at multiple healthcare facilities in an African field setting. Operational specificity and sensitivity were close to WHO-recommended thresholds. Since it was first described in December 2019 in Wuhan, Hubei Province in China, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 has caused a significant global public health problem (Wang et al., 2020) . As of 27 July 2021, SARS-COV-2 had resulted in 195,1963,640 infections resulting in 4,180,182 deaths in over 220 countries (COVID Live Update, 2021.) . Preventing the spread of SARS-COV-2 is a global public health priority requiring multiple interventions such as social distancing, hand hygiene, infection protection devices, vaccination, timely and accurate diagnosis, and treatment of the sick (Botti-Lodovico et al., 2021; Gates, 2020) . Reverse transcriptase-polymerase chain reaction (RT-PCR) of nasal/oropharyngeal samples is the gold standard diagnostic method of SARS-CoV-2 (Ishige et al., 2020) . Though RT-PCR has high sensitivity, it requires a robust infrastructure, well-trained staff, an elaborate supply chain to support testing services, and it comes at a high cost (Yüce et al., 2021) . In many LMICs, there are significant gaps to support RT-PCR testing, resulting in limited access to testing. Although a typical RT-PCR assay takes an average of 4-6 hours, in most countries, the time to get results is much longer due to logistics, inefficient reporting systems and lack of digital data management (Africa CDC, 2020; Mulu et al., 2021) . Furthermore, access is much more limited in hard-to-reach communities, making controlling the pandemic a problematic task. With low vaccination rates not exceeding 2% in Africa and across many low-and middle-income countries, testing remains a crucial pillar in the fight against SARS-COV-2 (Nachega et al., 2021; Sah et al., 2021) . In these settings, point of care Ag-RDTs provides a practical alternative to RT-PCR. Although Ag-RDTs may not fully replace RT-PCR testing, they offer an easy-to-use POCT method. Moreover, Ag-RDTs can easily be scaled to community settings since they do not require any equipment or well-trained laboratory staff. The quick turnaround time of 15-30 minutes helps in faster triage, rapid mass testing, correct patient placement, and, where applicable, support contact tracing (Rottenstreich et al., 2021) . The low cost per test and ease of use of Ag-RDTs makes them a suitable public health tool to widely scale-up testing in LMICs even in remote communities and in high transmission zones (Ricks et al., 2021; Rottenstreich et al., 2021) . The World Health Organization (WHO) recommends using antigen test kits with a sensitivity of at least 80% and specificity of greater than 97% compared to the gold standard RT-PCR (WHO, 2020) . In these settings, such Ag-RDTs provides a decent alternative to RT-PCR, hence the rapid increase in production of several such kits in the market within a short period. As of 25 July 2021, less than 20 months since the COVID-19 pandemic started, 176 listed antigen kits on the Foundation for Innovative New Diagnostics, (a global alliance for diagnostics that seeks to prioritize, partner, develop, evaluate, and support the equitable implementation of diagnostic tests) website (Escadafal et al., 2017; FIND, n.d.) . Although various kit manufacturers report the performance of their diagnostic kits, their operational performance can vary when subjected to the field or real-world conditions. Diagnostic performances of most Ag-RDTs in the market have yet to be adequately evaluated in field situations in LMICs. Moreover, most regulators carry out only limited, laboratory-based Ag-RDT evaluations before granting emergency use authorizations for use (Prince-Guerra et al., 2021) . This study aimed at an in-depth evaluation of the field performance of BioNote NowCheck COVID-19 Ag-RDT among Kenyans suspected to have COVID-19 attending four health facilities in Kisumu County, western Kenya. We conducted a cross-sectional, prospective diagnostic evaluation study comparing the Trained laboratory technicians collected paired nasopharyngeal and oropharyngeal samples from eligible participants attending four healthcare facilities in Kisumu County. Eligible participants met the Ministry of Health COVID-19 case definition and provided informed consent before sample collection. Pre-and post-test counselling services were provided as additional support for participants. The NowCheck SARS-CoV-2 Ag test is a rapid antigen chromatographic immunoassay for the qualitative detection of N protein of SARS-CoV-2 antigens(NowCheck COVID-19 Ag, n.d.). Trained health workers carried out the testing procedure according to the manufacturer's specifications. The results were provided to patients within 15-30 minutes of testing while awaiting final RT-PCR results within 24-48 hours. The results were digitally captured onto a tablet/smartphone application (digitized Kenyan COVID-19 Case Investigation Form) and stored in a safe cloud server as described here (Smith et al., 2019) , together with general information on the patients (such as age, gender and occupation). Results release, patient care and follow up was performed according to the Kenya Ministry of Health guidelines (Ministry of Health, 2020). RT-PCR testing was centrally performed at Kenya Medical Research Institute (KEMRI). The following thermocycling conditions were employed; 2 min at 25°C incubation, 10 min at 53°C for reverse transcription, 2 min at 95 °C for enzyme activation and 40 cycles of 3 s at 95°C and 30s at 60°C. Samples having exponential growth curve and Ct < 40 in at least two SARS-CoV-2 targets were considered positive, while those with Ct values in only one target were inconclusive. Assays with all targets, including MS2 negative, were deemed invalid. All invalid and inconclusive assays were repeated. All test procedures were performed according to manufacturer-prescribed protocols. The antigen test results were compared with gold-standard RT-PCR results and used to compute kit field performance specifications. Table 1 below provides the breakdown of paired antigen and PCR testing across the four facilities marked A to D. Analyses were performed using STATA-15 (StataCorp LLC, Texas, USA) and Microsoft Excel (Microsoft, Redmond, Washington, USA). We used descriptive statistics to describe the general information of study participants. Continuous data were summarized and presented in means, standard deviation (SD), median, and range as applicable. Categorical data were summarized in percentages, and a significance value of 0.05 in statistic tests was considered. Ag-RDT sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, positive predictive value, negative predictive value, and accuracy were calculated using MedCalc online software calculator (Schoonjans, n.d.) , grouped according to Ct values using the following cut-offs: 25, 30, 35 and 40 3. Results From 28 December 2020 and 31 March 2021, 997 eligible participants were enrolled in the study across four health facilities. The median age was 37 years (interquartile range, 28-49 years). Their demographic characteristics are summarized in Table 1 . The distribution of antigen and RT-PCR testing across the four participating health facilities in Kisumu County are summarized in Table 1 below. When compared against RT-PCR as the gold standard, the kit sensitivity and specificity showed variable performance across varying Ct values ( Testing is essential for controlling SARS-COV-2 infection, allowing early identification and isolation of cases to slow down transmission, and providing timely clinical management to those affected and protecting health systems operations through triaging at admissions (Taleghani and Taghipour, 2021) . In most LMICs, access to RT-PCR testing capacity is limited to a few specialized centres resulting in significant delays in testing (Kobia and Gitaka, 2020; Mina et al., 2020) . Ag-RDTs presents a suitable testing method with several advantages. These include low-cost, availability as point-of-care, easy to use, do not require electricity, specialized skills or special equipment. The lower cost per test and ease of rolling out to remote communities may offer opportunities to rapidly scale up to meet the high demand for testing, contributing to effective control of the pandemic (Peeling et al., 2021; WHO, 2020) . In its preliminary guidance on using SARS-CoV-2 rapid antigen kits, the WHO recommends using kits with a sensitivity of ≥ 80% and specificity greater than 97% (WHO, 2020) . In this study, we sought to evaluate the field performance of the NowCheck SARS-CoV-2 antigen kit in a field context, comparing it with the manufacturer's reported sensitivity and specificity of 89.2% and 97.3%, respectively. In this field evaluation, the BioNote NowCheck kit shows (Scohy et al., 2020) to 64% for the Alltest lateral flow immunoassay (Pérez-García et al., 2020) to kits with reported sensitivities higher than 80% such as Orient Gene, Deepblue, Abbott and Innova SARS-CoV-2 Antigen Rapid (Peto et al., 2021) . In a field evaluation study by Eliseo et al., similar to our study in a primary health centre, the Panbio Ag-RDT kit showed a sensitivity of 79.6% and specificity of 100% (Torres et al., 2021) . In a similar field evaluation of Standard Q Ag-RDT in Uganda, Nalumansi et al.(Nalumansi et al., 2021 ) noted a less than optimal performance with a sensitivity of 70% and specificity of 92%. The authors noted better performance at lower Ct values ≤29 with sensitivity exceeding 92%. The same finding was confirmed by Nahal et al. (Eshghifar et al., 2021) , who evaluated seven different rapid antigen kits and noted better performance at higher viral load, with an optimal Ct value of ≤25. To our knowledge, this is the first study in Kenya to extensively evaluate the field performance of an affordable COVID-19 Ag-RDT kit. The Ag-RDT kit showed excellent sensitivity and specificity compared to the gold standard, despite the challenges of the realworld environment. Such challenges included variability in sample collection practices among laboratory technicians across different healthcare facilities. Rapid turnover of healthcare staff required regular retraining. Growing stigma and fear due to curfews, lockdowns and stringent quarantine measures contributed to laboratory staff hesitation to collect samples (to the level of requesting 'danger allowances'). Shipment of samples to the central lab through motorbikes experienced cooling challenges. Patients became increasingly critical to getting tested, given the limited perspectives offered when testing positive. Stock-outs of reagents and kits for RT-PCR occurred, as well as (temporary) breakdowns of crucial lab equipment. In general, the Ag-RDT kit proved easy to use, requiring limited training time. Patients' discomfort during sample taking was reportedly minimal, and they appreciated an earlier (preliminary) COVID-19 test result. Patients and health workers considered the immediate availability of pre-and post-test counselling services of good value in nudging subsequent patient behaviour, including quarantining, support of contact tracing and hospitalization of those in need. This study provides a proof of concept that rapid antigen kits can easily be rolled out to the community level to support the quick point-of-care diagnosis that allows rapid patient triage, quarantining and hospital placement. In areas with limited access to RT-PCR testing and high patient flow, Ag-RDTs can be scaled up to remote locations, support quick turnaround times for test results with minimal training requirements. Rapid testing can help quick and effective contact tracing at the point of care, supporting efforts to contain SARS CoV-2 spread within the community. Though helpful, the limitations of these kits should be noted by the users. Some studies have suggested low sensitivity in screening asymptomatic patients (Eshghifar et al., 2021; Peña et al., 2021; Torres et al., 2021) . Various authors have cited lower sensitivity in patients with low viral load (high Ct values on RT-PCR); hence RT-PCR testing should continue to be offered where clinical suspicion is high (Ebrahimi et al., 2021; Nalumansi et al., 2021; Peeling et al., 2021) . The users should follow manufacturers laid down testing procedures to avoid potentially misleading false-negative or false-positive results. Funding Achmea Foundation, Pfizer Foundation, Dimagi and the Netherlands Ministry of Foreign Affairs supported this project. The funding sources did not have any role in study design, data collection, analysis, interpretation, summarizing the data or decision to submit the manuscript for publication. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. New guidance to expand rapid antigen testing for COVID-19 response in Africa released COVID Live Update: 194,969,465 Cases and 4,178,305 Deaths from the Coronavirus -Worldometer Diagnostic Utility of Antigen Detection Rapid Diagnostic Tests for Covid-19: A Systematic Review and Meta-Analysis New Biomarkers and Diagnostic Tools for the Management of Fever in Low-and Middle-Income Countries: An Overview of the Challenges Evaluation of Analytical Performance of Seven Rapid Antigen Detection Kits for Detection of SARS-CoV-2 Virus Responding to Covid-19 -A Once-in-a-Century Pandemic? Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories COVID-19: Are Africa's diagnostic challenges blunting response effectiveness? Rethinking Covid-19 Test Sensitivity -A Strategy for Containment The challenges of COVID-19 testing in Africa: the Ethiopian experience Field evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda using nasopharyngeal samples Scaling up COVID-19 rapid antigen tests: promises and challenges. The Lancet Infectious Diseases Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites -Pima County Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis Rapid antigen detection testing for universal screening for severe acute respiratory syndrome coronavirus 2 in women admitted for delivery Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants MedCalc's Diagnostic test evaluation calculator Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis Connected diagnostics: linking digital rapid diagnostic tests and mobile health wallets to diagnose and treat brucellosis in Samburu, Kenya Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art Evaluation of a rapid antigen test (Panbio TM COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients A novel coronavirus outbreak of global health concern COVID-19 diagnosis -A review of current methods Authors Contributions SON: Data curation; Formal analysis; Investigation; Methodology; Visualization; Writingoriginal draft; Writing -review & editing; KO: Investigation Supervision; Validation; Writing -review & editing: SVD: Data curation Investigation; Methodology; Writing -review & editing; EA: Methodology; Validation Visualization; Roles/Writing -original draft; Writing -review & editing Roles/Writing -original draft; Writingreview & editing; IAO: Investigation; Methodology Software; Supervision; Validation; Visualization Roles/Writing -original draft; Writingreview & editing; AK: Data curation; Formal analysis; Software; Supervision; Validation Writing -review & editing; NH: Conceptualization; Funding acquisition Roles/Writing -original draft; Writing -review & editing; EM: Investigation; Methodology Supervision; Writing -review & editing; RA: Investigation; Methodology; Project administration; Validation Roles/Writing -original draft; Writing -review & editing; HCB: Conceptualization; Funding acquisition; Investigation; Methodology Writing -review & editing; FO: Conceptualization; Funding acquisition Investigation; Methodology AO: Conceptualization; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Writing -review & editing SK: Conceptualization; Funding acquisition; Investigation; Methodology Data curation; Formal analysis; Funding acquisition; Investigation; Methodology 1% (98.3-99.5) 98.16% (97.1% The Netherlands Ministry of Foreign Affairs supported this work through a core grant to Health Insurance Fund Foundation, which supports PharmAccess Foundation and by complementary grants from Achmea Foundation and Pfizer Foundation. The CommCare mobile data collection software was provided by Dimagi free of charge. BioNote Inc provided free RDTs for evaluation. Many thanks to all staff who supported this project.